Pharma BD Deal Intelligence

Amneal Pharmaceuticals, Inc. / Kashiv BioSciences, LLC

2026 · Acquisition/Merger · $1.1B · Pending

Announcement Sentiment

Strongly positive

Amneal (AMRX) entered a definitive agreement to acquire 100% of Kashiv BioSciences for $375M cash plus $375M equity at closing and up to $350M in regulatory-milestone and commercial-royalty payments, plus operating funding through closing. Establishes a fully integrated global biosimilars platform.

Key facts

Announced Apr 22, 2026
Deal value $1.1B
Deal type Acquisition/Merger
Therapeutic area biosimilars (cross-therapeutic; positioned for $300B+ biologics LOE wave)
Indications biosimilars (cross-therapeutic; positioned for $300B+ biologics LOE wave)
Key assets Kashiv biosimilars development and manufacturing platform plus biosimilars pipeline

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals